Amedisys Inc (NASDAQ:AMED) Director Jake L. Netterville sold 4,096 shares of the business’s stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $80.44, for a total value of $329,482.24. Following the completion of the transaction, the director now directly owns 77,660 shares in the company, valued at approximately $6,246,970.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of AMED traded up $1.70 during mid-day trading on Thursday, hitting $83.81. The stock had a trading volume of 8,653 shares, compared to its average volume of 279,357. The firm has a market cap of $2.79 billion, a PE ratio of 37.78, a PEG ratio of 1.42 and a beta of 0.64. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.63 and a quick ratio of 1.63. Amedisys Inc has a 52 week low of $45.60 and a 52 week high of $82.69.
Amedisys (NASDAQ:AMED) last issued its earnings results on Monday, May 7th. The health services provider reported $0.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.12. The firm had revenue of $399.30 million for the quarter, compared to analyst estimates of $395.38 million. Amedisys had a return on equity of 16.83% and a net margin of 2.71%. The business’s revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.47 earnings per share. sell-side analysts anticipate that Amedisys Inc will post 3.11 earnings per share for the current fiscal year.
Several research analysts have weighed in on AMED shares. TheStreet raised Amedisys from a “c+” rating to an “a-” rating in a research report on Monday, May 7th. BidaskClub raised Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 6th. Royal Bank of Canada raised Amedisys from a “sector perform” rating to an “outperform” rating in a research report on Monday, March 19th. Robert W. Baird boosted their price objective on Amedisys to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 8th. Finally, Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $74.00 price objective on the stock in a research report on Tuesday, May 1st. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $70.55.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.